Real-life requests for Bordetella polymerase chain reaction testing in children presenting to hospital

From 2015 to 2017, 3197 interpretable Bordetella polymerase chain reaction (PCR) tests were performed for 2760 children presenting to our tertiary university hospital. Requests mainly came from the emergency department (62%) and for children older than 1 year (68%). Only 32 PCR (1%) results were positive, mainly in children younger than 1 year (n = 29/32, 90.6%; p<0.001). When focusing on the PCR indications in 2017, we found the requests were mainly based on nonspecific respiratory symptoms and were clinically unjustified in 383 cases (39%). Pediatricians overused Bordetella PCR in clinical practice. They should reserve their requests for cases of young children with symptoms suggestive of respiratory illness and/or incomplete pertussis immunization.

Erratum: Inhaler technique: facts and fantasies. A view from the Aerosol Drug Management Improvement Team (ADMIT)

[This corrects the article DOI: 10.1038/npjpcrm.2016.17.].

[Bench-test evaluation of spacer devices for fluticasone delivery to infants]

INTRODUCTION

Use of a spacer device to optimize the delivery of fluticasone to infants with asthma is an important issue and clinicians require guidance around the choice of device. This in vitro study characterizes the particle size and the fluticasone delivery via 9 spacers.

METHODS

We used an in vitro infant nasal cast with two different inspiratory flow rates (50 and 100mL/s). Fluticasone particle size in the aerosol was evaluated by laser diffractometry and tracheal deposition by spectrophotometric assay.

RESULTS

Significant differences in particle size were observed between the 9 spacers (similar D50 but D90 from 5.65±0.65 to 8.80±1.35μm). A 75 % or higher respirable fraction was obtained for only 5 spacers. The 50mL/s flow rate lead to the best drug delivery. At this flow, OptiChamber^® (62±3 %) and Vortex^® (91±8.5 %) had a tracheal deposition over 50 % of the initial dose of fluticasone, although the 7 other spacers exhibited a fluticasone deposition less than 25 %.

DISCUSSION

This study shows a wide variation of drug delivery between the 9 spacers studied. We demonstrate that a low inspiratory flow and a spacer showing antistatic properties facilitate drug delivery.

Inhaler technique: facts and fantasies. A view from the Aerosol Drug Management Improvement Team (ADMIT)

Health professionals tasked with advising patients with asthma and chronic obstructive pulmonary disease (COPD) how to use inhaler devices properly and what to do about unwanted effects will be aware of a variety of commonly held precepts. The evidence for many of these is, however, lacking or old and therefore in need of re-examination. Few would disagree that facilitating and encouraging regular and proper use of inhaler devices for the treatment of asthma and COPD is critical for successful outcomes. It seems logical that the abandonment of unnecessary or ill-founded practices forms an integral part of this process: the use of inhalers is bewildering enough, particularly with regular introduction of new drugs, devices and ancillary equipment, without unnecessary and pointless adages. We review the evidence, or lack thereof, underlying ten items of inhaler ‘lore’ commonly passed on by health professionals to each other and thence to patients. The exercise is intended as a pragmatic, evidence-informed review by a group of clinicians with appropriate experience. It is not intended to be an exhaustive review of the literature; rather, we aim to stimulate debate, and to encourage researchers to challenge some of these ideas and to provide new, updated evidence on which to base relevant, meaningful advice in the future. The discussion on each item is followed by a formal, expert opinion by members of the ADMIT Working Group.

Pulmonary sequestration of the left upper lobe associated with a bronchogenic cyst: case report of an exceptional association

Intralobar pulmonary sequestration (ILPS) and bronchogenic cyst are rare congenital diseases. We present the first case of the association between an ILPS located in the upper lobe and a bronchogenic cyst. This association has been discovered antenatally in a girl. The cystic lesion has been shown by a fetal MRI and confirmed by a CT scan at 3 weeks of life. She underwent a left upper lobectomy by thoracoscopy at the age of 5 months. Postoperative course was uneventfull. This case confirms the congenital origin of pulmonary sequestration and shows the interest of an early surgery.

Management of young children in contact with an adult with drug-resistant tuberculosis, France, 2004-2008

SETTING

Drug-resistant tuberculosis (DR-TB) is increasing worldwide and may be a source of diagnostic and therapeutic problems in young exposed children. In France exposed children are systematically treated with 3-month isoniazid-rifampicin prophylaxis.

OBJECTIVE

To describe the characteristics and management of children aged <2 years in contact with an adult case of DR-TB in France over a 5-year period (2004-2008).

METHODS

Children were retrospectively identified by sending questionnaires to all the members of the Paediatric Infectious Diseases Group and the Paediatric Pulmonology Group of the French Paediatric Society.

RESULTS

Ten children, all infants, in contact with an adult case of DR-TB were identified: six cases of DR-TB (mean age 4.6 months), one case of TB infection and three cases of exposure (mean age 3.1 months). The children were mainly in contact with poly- or multidrug-resistant TB. Time to initiation of appropriate treatment was 39 days for TB disease and 58 days for TB infection or exposure. One child with TB infection developed TB disease due to failure to adapt prophylaxis. Treatment was variable and centre-dependent. Short-term follow-up showed complete recovery of all children.

CONCLUSION

Management of young children in contact with adult DR-TB requires rapid identification of the drug resistance profile. Molecular techniques should be used to reduce delays in initiating appropriate treatment.

Association of three different congenital malformations in a same pulmonary lobe in a 5-year-old girl

We report the case of a 5-year-old girl with persistent chest X-ray abnormalities following an episode of pneumonia who has a complex congenital pulmonary malformation comprising of a congenital pulmonary airway malformation, an intralobar sequestration and two bronchogenic cysts, all present within the same lobe. The observation suggests a common embryological origin of these malformations.

[A survey of nebulization practices in France conducted in 2004 by the GAT]

METHODS

A questionnaire was sent to 50 000 general practicioners (GP) and specialists.

RESULTS

4,898 physicians (9.4%) responded, including 59.1% GP, 16.9% pneumologists, 13% pediatricians and about 10% other specialists, ENT, allergologists, and intensivists. The main reason for pneumologists to prescribe nebulization was the efficiency on long term of approved drugs. GP prescribe nebulization for its local effects, using unapproved drugs, on short periods of time, especially in COPD, asthma, bronchitis and tracheitis/laryningitis. Although pneumologists have been trained during their fellowship and do not ask for further education, MG have learned by their own experience and are asking for further education.

CONCLUSION

This study should help to develop teaching programs on nebulization with the aim to optimize its practice.

[3-min step test: feasibility study for children with bone marrow transplantation]

INTRODUCTION

Bronchiolitis obliterans following a bone marrow transplantation needs an early diagnosis for a better evolution. First signs are exercise dyspnea and hypoxemia. A walking test evaluating the tolerance for effort could have an interest in detecting such symptoms. We report a preliminary study of feasibility of the 3-minute step-test in children with a bone marrow transplantation.

METHODS

Ten patients (5 boys, median 11.7 years, range 5.1-15.5 years) were included within at least 3 months away from a bone marrow transplantation. After clinical examination and realisation of pulmonary function tests, the test was to step up and down a single step which is 15 cm high, rhythmically (30 per minute) during 3 minutes. Heart rate and pulsed oxygen saturation were registered, dyspnea being assessed before and after the test by means of a visual analogue score and the fifteen-count breathlessness score.

RESULTS

All the children realised the 3-minute step-test successfully and with excellent tolerance. Only 1 child made an effort judged maximum. No hypoxemia caused by the effort was highlighted.

CONCLUSION

The 3-minute step-test is easy to achieve in a population of paediatric patients who have undergone a bone marrow transplantation. It could be a valuable tool in the respiratory follow up of these children.

N.U.A.G.E.S: A survey of nebulisation practice in France with regard to ERS guidelines

A survey of nebulisation practice in France was conducted under the aegis of the French respiratory society in 2004.

METHODS

Analysis of a questionnaire was obtained from 3674 physicians.

RESULTS

A total of 2439 physicians were general practitioners (GPs), 698 were chest physicians, and 537 paediatricians. The main reasons to use nebulisation are (1) for chest physicians efficacy in treating various pathologies with long-term administration (1 wk to 1 month) of approved drugs, and (2) for GP's local action properties. While chest physicians learned about nebulisation during their university training and do not ask for additional information, GPs learned by practical experience or from colleagues and ask for further information.

CONCLUSION

This study will help to develop targeted educational programmes on nebulisation practice.

[The effects of tobacco on children]

INTRODUCTION

Smoking remains an important topic. It is estimated that at present half the children born in France have been, or will be, exposed to the toxic effects of passive smoking. This paper aims to review the evidence of the effects of passive smoking, both intra and extra-uterine.

STATE OF THE ART

Extra-uterine passive smoking is implicated in numerous respiratory (asthma, allergy, infections...) and non respiratory diseases (neoplastic, dental, ophthalmic, digestive, cardio-vascular and infective). Intra-uterine exposure is even more dangerous and leads to abnormalities of the pregnancy (placental abnormalities, prematurity...), of the foetus (behavioural problems, malformations) and long term problems for the unborn child. Passive smoking is responsible for pulmonary morphological abnormalities (pulmonary hypoplasia, reduction in elasticity, increased deposition of collagen and alteration of alveolar structure) and functional disorders (reduced compliance, increased airways resistance, bronchial hyperreactivity). Finally it causes a disturbance of respiratory control, promoting all the factors responsible for sudden cot death.

CONCLUSIONS

The ill effects of passive smoking fully justify efforts to inform and persuade the medical profession of its duty to fight this scourge.

Les nouveaux tests diagnostiques de la tuberculose

INTRODUCTION

A major challenge in tuberculosis (TB) control is the diagnosis and the treatment of latent tuberculosis infection.

STATE OF THE ART

At the time, the diagnosis is based on tuberculin skin test (TST). TST is not specific, has poor sensitivity and is not easy to perform.

PERSPECTIVES

Two interferon-based tests for the diagnosis of tuberculosis have just been licensed. These tests have some advantages on TST. They require only a blood sample and their results are not dependent on the examinator. Their specificity is higher than TST because they don't cross-react with BCG vaccination and with most of the environmental Mycobacterium species. Their sensitivity is higher for the diagnosis of active tuberculosis too. For latent tuberculosis, the interferon-gamma assays show a better correlation with the exposure to Mycobacterium tuberculosis than TST. The ability to detect TB of the two tests seem to be reduced in immunocompromised patients, specially in medically ones.

CONCLUSIONS

Interferon-gamma assays seems to be useful tools in TB detection, but these good results have to be confirmed in larger studies with unselected patients.

The need to improve inhalation technique in Europe: a report from the Aerosol Drug Management Improvement Team

Although the principles of asthma management are well established in Europe, the available data indicate that asthma in patients is not well controlled. Many patients derive incomplete benefit from their inhaled medication because they do not use inhaler devices correctly and this may compromise asthma control. The Aerosol Drug Management Improvement Team (ADMIT), incorporating clinicians from the UK, Germany, France, Italy, Spain and The Netherlands, reviewed published evidence to examine ways to improve the treatment of reversible airways disease in Europe. Data indicate that there is a clear need for specific training of patients in correct inhalation technique for the various devices currently available, and this should be repeated frequently to maintain correct inhalation technique. Devices which provide reassurance to patients and their physicians that inhalation is performed correctly should help to improve patient compliance and asthma control. Educational efforts should also focus on primary prescribers of inhaler devices. ADMIT recommends dissemination of information on the correct inhalation technique for each model of device by the use of an accessible dedicated literature base or website which would enable to match the appropriate inhaler to the individual patient. There is also a need for standardisation of prescribing practices throughout Europe. Regular checking of inhalation technique by prescribers is crucial as correct inhalation is one of the keystones of successful asthma management.

Caractéristiques d'une épidémie de grippe A chez l'enfant (2003–2004). Impact sur l'activité des services d'urgences et de médecine pédiatriques

AIM OF THE STUDY

To describe epidemiological features of an outbreak of flu A in hospitalized children and to evaluate the flu's burden in pediatric and pediatric emergencies departments.

POPULATION AND METHODS

Multicenter prospective study in 2 pediatric university hospitals, in Marseille, France. Nasal swabs for flu A were performed in all the febrile children admitted during winter 2003-2004. Pre and postoutbreak admissions in pediatric and pediatric emergencies departments were compared too.

RESULTS

During the outbreak, 941 children were admitted and 605 were tested for flu A. Nasal swabs were positive in 111. Attack's rate was 11.8%. In these children, infants under 2 years were 66%. Respiratory forms were uncommon, although febrile seizures and digestive troubles were much frequent. The mean hospitalization duration was almost 4 days. Flu A outbreak finally increased the pediatric and pediatric emergencies departments rates of admission, of 48% and 37% respectively.

CONCLUSION

Flu is frequently underestimated in children, especially in infants. Clinical forms are various. Child's vaccination is questionable in France.

[Nebulisation in childhood asthma]

The inhaled route way, which directly brings an appropriate amount of drug in the right place, is at the present time the recommended route for asthma treatments. The development of spacer devices, easier to use, has reduced the indications of nebulised treatments, but these are still essential in some situations. Nebulisation of short acting beta-2-agonists, which usually requires oxygen administration, is still the first line treatment of a severe acute asthma attack. Ipratropium bromide can be added in the nebulisation, depending on the severity of the attack and the response to beta-2-agonists. Sodium cromoglycate is not used in the prophylactic treatment of childhood asthma any more, but nebulised budesonide is still very useful in moderate to severe persistent asthma in children under 5 years of age, after failure of a treatment with a spacer device. The quality of nebulisation is fully dependent on the equipment used, and on the practical conditions of its realization. It is of most extreme importance to use a compressor/nebulizer couple which is validated for the delivered drug, and that the child breathes, depending on age, via a mouth peace or a facial mask.

[Cystic intrathoracic hemolymphangioma: a rare differential diagnosis of acute bronchiolitis in an infant]

Hemolymphangioma is a benign malformation of the lymphatic vessels. Cervical localisation is the most frequent. Mediastinal localisation is rare, but may be life-threatening because of airway compression. We report on a four-month-old boy who presented, in a context of epidemics, with clinical signs of acute bronchiolitis requiring mechanical ventilation for several days. Chest X-rays showed an important mediastinal mass with airways compression. Diagnosis was evoked on CT-scan aspects and confirmed by histology. Surgery allowed complete resolution, but dysphonia and oropharyngeal disorders persisted for several months. This rare congenital malformation is reviewed.

Emitted doses of salbutamol pressurized metered-dose inhaler from five different plastic spacer devices

In a recent clinical study we have demonstrated that the bronchodilator effect of 200 microg salbutamol (Ventoline) was spacer device-dependent in 100 tested asthmatic children, with the Babyhaler providing greater efficacy for improving peak expiratory flow rate compared to Aeroscopic, Nebuhaler, Aerochamber and Volumatic. The aim of this present study was to correlate our clinical results to in vitro determinations of the emitted dose (ED) of Ventoline administered via these five different plastic spacer devices. ED was determined from the mean of single doses collected in unit dose sampling tubes using a constant suction flow of 28.3 L/min. Three pressurized metered-dose inhalers and three sets of spacer devices were used to obtain a total of 30 measurements per group. Inter-group results were compared by RM-ANOVA or Student-Newman-Keuls method when indicated. Babyhaler delivered significantly (P < 0.05) more salbutamol than Nebuhaler, Aerochamber and Aeroscopic (mean +/- standard deviation: 63.6 +/- 2.9 microg/100 microg actuation for Babyhaler vs. 59.4 +/- 8.6 for Nebuhaler, 50.8 +/- 5.0 for Aerochamber and 47.5 + 2.5 for Aeroscopic). The ED from Volumatic (61.5 +/- 7.9 microg/100 microg actuation) was similar to that from the Babyhaler. The variability in the ED was greatest with the large volume spacers. Despite a greater ED from the Babyhaler, in vitro results do not fully explain the in vivo results. However, the previously described clinical improvement seen with the Babyhaler may be due to the quantitatively different aerosol production in a more 'useful' size range, as well as the different breathing patterns of the children tested. The results of this present study question the relevance of mouthpiece filter collection studies using a constant sampling in predicting clinical or physiological outcomes.

La fibroscopie bronchique chez l’enfant

INTRODUCTION

Fibreoptic bronchoscopy (FB) is an important diagnostic examination in paediatric pulmonology. In 2002 the Paediatric Pulmonology and Allergy Club undertook a retrospective study to establish the current status of fibreoptic bronchoscopy among its members.

METHODS

In 2001 sixty five paediatric pulmonologists carried out an average of 116 examinations (+/- 111) in 35 paediatric centres. FB was performed either in an operating theatre (15 centres), a dedicated bronchoscopy suite (6 centres) or an endoscopy suite shared with gastro-enterologists (7 centres). Other examinations were performed in areas dedicated to, or associated with intensive care. General anaesthesia was routinely used in 18 centres. The others used sedation including an equimolar mixture of oxygen and nitrous oxide in 14 centres. Ten centres performed less than 50 examinations, 12 between 51 and 100, 4 between 101 and 200 and 8 centres more than 200 in the year. Seventy two per cent of the children were less than 6 years old. The washing and disinfection procedures were manual in 20 centres and automatic in 15.

RESULTS

Three principal indications were reported: persistent wheezing, suspicion of a foreign body and ventilatory difficulties. Cough, desaturation and fever were the most frequently reported side effects.

CONCLUSIONS

This is the first survey in paediatric pulmonology in France. It shows a wide variation in the practice of fibreoptic bronchoscopy in children.

Délivrance des traitements inhalés en pédiatrie

The most efficient method to deliver drugs to the lungs in children is the inhaled way. Its success depends on the characteristics of the aerosol, on those of the patient, and mainly on the inhalatory system. Before the age of 8 years, the most efficient system is the pressurised metered dose inhaler used together with a spacer device. Above this age, the use either of the pressurised metered dose inhaler, with a spacer device or a breath-actuated inhaler, or of a dry powder inhaler is discussed. Nebulisation is rarely indicated, except in cystic fibrosis. Demonstration with repeated medical instructions allows adequate inhalation technique. Inhaled treatments are efficient when used in diseases requiring this type of treatment, when several inhalers with different inhalatory techniques are not prescribed together, and when delivery is once or twice daily. At last, inhaled way is a new approach for different drugs with an extra-respiratory activity.

Electrostatic charge on spacer devices and salbutamol response in young children

Electrostatic charge on plastic spacer devices may affect the efficacy of inhaled drugs, but its consequences have never been evaluated in asthmatic children with airflow limitation. At the end of a positive metacholine challenge, 64 children (51.3+/-12.9 months, 32 boys, specific airway resistance (SRaw) 257.1+/-56.7% and forced expiratory volume in 1s (FEV(1)) 64.2+/-17.9% of the predicted value) inhaled one puff of hydrofluoroalkane-134a (HFA-134a) salbutamol (Ventoline((R))), and 15min later two other puffs (total dose of 300 microgram), delivered through either a new static Babyhaler((R)) (n=21), a detergent-coated, reduced static, Babyhaler((R)) (n=20), or a metal NES-Spacer((R)) (n=23) equipped with facemask. SRaw and FEV(1) were measured after each treatment and compared between groups by a Kruskal-Wallis test. The first 100 microgram salbutamol induced a 151.7+/-43.9% decrease in SRaw and a 19.9+/-10.6% increase in FEV(1). Additional 200 microgram salbutamol allowed a supplementary decrease of 35.1+/-25.7% in SRaw and increase of 12.1+/-11.8% in FEV(1), without significant difference between the spacer devices. Electrostatic charge on spacer devices does not affect bronchodilation with HFA-134a salbutamol in metacholine-challenged pre-school children. This could be in part explained by the use of supramaximal doses of salbutamol.

[The beta-2-agonists in asthma in infants and young children]

beta 2-agonists, by inducing a fast and long relaxation of the bronchial smooth muscle, are considered as the more potent bronchodilators. beta 2-receptors are present from the 16th gestational week, explaining a possible bronchial response in the youngest children. beta 2-agonists do not induce any bronchodilator response in healthy children. Short-acting beta 2-agonists (salbutamol or albuterol, terbutaline) are indicated for asthma attacks, as needed in chronic asthma, and for prevention of symptoms during effort. They are safe and secure. The more efficient route of administration in preschool children is pressurized metered-dose inhaler used with a spacer device. Therefore, whatever the route of inhalation chosen (inhalation, injection, or continuous nebulization in acute asthma attack), more specified indications and doses are needed in young children. Long-acting beta 2-agonists (formoterol, salmeterol) are not authorized in France in children under 4 to 5 years of age depending on the drug used. Because of new oral formulations and recent considerations about their use in asthma attack, instead of short-acting beta 2-agonists, their indication in preschool asthmatic children might be reconsidered.

[Inhalers and nebulizers in the children]

Inhaled way is the most efficient method to deliver drugs for the treatment of respiratory diseases. Pulmonary deposition depends upon the inhalation system and technique. The evaluation of the drug deposition is difficult, particularly in children. Because of irradiation, scintigraphic studies which permit the best approach of the pulmonary deposition are rare in children. Various inhalation systems are available: nebuliser, metered-dose inhaler with or without spacer device, dry powder inhaler. Whatever the system used, the control of asthma will be only possible with the regular evaluation of the child inhalatory technique.

Local side-effects of inhaled corticosteroids in asthmatic children: influence of drug, dose, age, and device

BACKGROUND

The objective was to investigate the local side-effects of inhaled corticosteroids (ICS) in daily life in asthmatic children, particularly the younger ones, by an observational prospective cross-sectional cohort study.

METHODS

Asthmatic children (n=639, 75.9+/-48.9 months, 61.3% boys), treated with beclomethasone dipropionate (BDP) (721.0+/-287.3 microg per day) or budesonide (BUD) (835.5+/-684.9 microg per day) for at least 1 month, were recruited at the time of a scheduled visit. Local side-effects were researched by questionnaire (cough during inhalation, hoarseness, dysphonia, and thirsty feeling) and clinical examination (perioral dermatitis, oral candidiasis, and tongue hypertrophy).

RESULTS

Exactly 63.3% of the children aged under 6 years and 59.5% of the older ones reported one local side-effect. Cough (39.7%) was dependent on young age, use of BDP, and mainly use of spacer device, with an OR of 4.7 (95% CI: 2.7-8.2). Thirsty feeling (21.9%) and hoarseness (14.1%) occurred in children using ICS and long-acting beta2-agonists. Dysphonia (11.1%) was favored by high doses of BDP and BUD, and by inhalation from spacer devices or nebulizers. No factor favored oral candidiasis (10.7%). Perioral dermatitis (2.9%) and tongue hypertrophy (0.1%) were associated with nebulization.

CONCLUSION

Local side-effects of ICS are common in asthmatic children of all ages, and the device used constitutes the most influential factor.

Delivery of salbutamol pressurized metered-dose inhaler administered via small-volume spacer devices in intubated, spontaneously breathing rabbits

Little is known about the ability of small-volume valved spacer devices to deliver a significant amount of an aerosolized drug to the lungs of babies. This study compared the in vitro delivery of salbutamol administered via Aerochamber-Infant (145 mL), Babyhaler (350 mL), and metallic NES-spacer (250 mL), as well as the in vivo delivery using an animal model. The lung deposition study of technetium-99m-labeled salbutamol was conducted in six anesthetized, intubated (3.0-mm endotracheal tube simulating oropharyngeal deposition), spontaneously breathing New Zealand White rabbits, a model for 3-kg babies. Each rabbit was studied on three separate occasions, once with each spacer device. The amount of radioactivity deposited in the spacer device, the endotracheal tube, the lungs, or the body was measured by a gamma camera and expressed as a percentage of the emitted labeled dose. The emitted dose and particle size distribution of salbutamol via the three spacer devices were measured using unit dose sampling tubes and an eight-stage Anderson cascade impactor, respectively. The results were compared by ANOVA or Student-Newman-Keuls test when indicated. In vitro, the NES-spacer and Babyhaler were equivalent for delivering particles <5.8 microm in diameter (NES-spacer = Babyhaler > Aerochamber-Infant; p < 0.05). In vivo, the lung and body deposition was low with all spacer devices (range: 0.52-5.40% of the delivered dose) but greater with the NES-spacer than with the Aerochamber-Infant or the Babyhaler (5.40 +/- 2.40%, 2.91 +/- 0.86%, 0.52 +/- 0.46%, respectively; p = 0.002). These results suggest the metal-valved spacer device may be preferable for delivering pressurized aerosols to spontaneously breathing infants.

Delivery of HFA and CFC salbutamol from spacer devices used in infancy

The aim of the study was to compare the in vitro delivery of four salbutamol pressurized metered-dose inhalers (pMDIs) via the three spacer devices commonly used in European infants: Aerochamber-Infant, Babyhaler, and metallic NES-spacer. Emitted dose (ED) and fine particle dose (FPD, particles<5.8 microm) of each combination of spacer device and pMDI (chlorofluorocarbon-based Ventoline, Eolène, Spréor, and hydrofluoroalkane-based Airomir were measured respectively using unit dose sampling tubes (n=30 per combination) and an 8-stage cascade impactor (n=6 per group). The results were compared by analysis of variance and the Student-Newman-Keuls method. ED of Airomir was always greater than for Ventoline (P<0.05). FPD obtained with Ventoline was the lowest, with Eolène>Airomir=Spréor>Ventoline (P<0.05). Only Airomir produced a similar FPD with all three spacer devices. Chlorofluorocarbon-salbutamol pMDIs are not generics when used with spacer devices. The three spacer devices may be used interchangeably with Airomir.

[Inhalation spacer devices in childhood asthma: is utilization easy?]

IMPROVED DRUG DELIVERY: Spacer devices improve the pulmonary deposition of drugs delivered from pressurized metered-dose inhalers because they decrease the diameter of the aerosol particles. Spacer devices are the best delivery system of inhaled drugs in children younger than 8 years.

TECHNICAL ASPECTS

Small volume spacer devices, with inspiratory and expiratory valves, are particularly interesting to use. The use of a facemask is only recommended in the youngest and the oldest have to breathe through the mouth piece. Electrostatism is generated from the plastic walls of the spacer devices and decreases the drug delivery. Using a metallic spacer device or washing a plastic spacer device with a domestic detergent, without rinsing with water nor rubbing the walls, avoids this problem. OPTIMAL USE: Spacer devices are not generics. Each drug has a specific behaviour in a spacer device. Correct inhalatory technique has to be checked at each visit for an optimal efficacy of the treatment.

[Virus and respiratory allergy in children]

Links between viruses and respiratory allergy are not easy to understand in children. For example, the risk of atopy or asthma is increased after an infection with syncytial respiratory virus. In some studies, more the child suffers from viral infections, more the risk of atopy increases. On the other hand, other studies state that the development of allergy is reduced if a child enters day nursery before 12 months, and consequently if he is exposed early in life to viruses. Measles and hepatitis A viruses could also protect from allergy. In fact, viruses seem modulate the expression of a preexisting atopic status. Depending on their nature and their circumstances of occurrence, they could induce some sensitizations or inversely protect from atopy by facilitating the lymphocyte Th2 or Th1 response.

[Role of leukotriene inhibitors in the treatment of childhood asthma]

Leukotriene inhibitors are new pharmacological agents for the treatment of mild to moderate persistent asthma and exercise-induced asthma (EIA). Studies concerning their use in children remain scarce. Available data in the treatment of persistent asthma in children suggest that they could be an alternative to long-acting beta 2-agonists when asthma control cannot be obtained with inhaled steroids alone. Their main advantages are first that they are given orally once daily; second, that they do not induce tachyphylaxis to bronchoprotection against EIA, unlike long-acting beta 2-agonists. Studies specifically conducted in children are necessary to best describe their place in pediatric asthma treatment.

[Respiratory allergy in children and passive smoking]

Environmental tobacco smoke interacts with the respiratory mucosa by irritation and/or inflammation. Environmental tobacco smoke seems also modulate humoral and cellular immune activity. Thus, environmental tobacco smoke, in all children, increases the risk of superior and inferior airway infections, modifies the growth and the natural evolution of the respiratory function, increases the occurrence of asthma and exacerbates the symptoms of asthma, and creates or exacerbates a bronchial hyperresponsiveness. In atopic children (defined by the presence of at least one positive allergy skin test), environmental tobacco smoke increases the risk of respiratory allergy and exacerbates the symptoms of respiratory allergy. Parental environmental tobacco smoke is a universal toxic which must be avoided in both allergic and non-allergic children.

[Non-antibiotic treatments for community-acquired pneumonia in children]

Besides antibiotic therapy (when warranted), treatment of acute pneumonia in children usually requires only simple measures, including: fractionated feeding, analgesic and antipyretic medications and detection of hypoxemia. There is no evidence that physical chest therapy, bronchial mucus modificators and corticosteroid therapy are really useful. The best prevention relies upon vaccinations, suppression of passive smoking, and hygiene and nutritional improvements.

[Ontogeny of the immune system]

The newborn immune system differs quantitatively and functionally from adults. At birth, the immune system is partially immature, resulting in deficiency in cell-mediated cytolysis, immunoglobulin synthesis and cytokine production. The most clearly defined deficit in neonatal phagocytosis defenses is diminished neutrophil storage. T cell function is diminished, including T cell-mediated cytotoxicity and T cell help for B cell differentiation. Selective decreases in cytokine production by T cells may contribute to all of these deficits. One of the fundamental differences between adults and newborns for T cell functions resides in whether or not the patient had prior exposure to antigens. Significant immune responses to antigens can be obtained in the neonatal period. These responses are qualitatively different from those induced in adults with a predominance of TH2 pattern.

[Acute asthmatic crisis in children]

Acute asthma attack in children is an attack responsible for life-threatening acute respiratory distress with partial or no response to bronchodilator drugs. The severity of the episode needs to be quickly evaluated. This presupposes a perfect knowledge of the clinical signs of severity. Treatment is urgent and first based on the administration of high doses of inhaled short-acting beta 2-agonists. In the more obstructed children, anti-cholinergic drugs can be added to nebulized beta 2-agonists. Because of their delayed effect, systemic steroids require an early prescription. Symptomatic treatments are: urgent hospitalization, oxygen if needed, proper hydratation. Continuous nebulization or intravenous perfusion of beta 2-agonists are prescribed with cardiac monitoring when no objective improvement is noted. Admission into the pediatric intensive care unit when bronchial obstruction continues will permit the association of bronchodilator drugs and the proposal of mechanical ventilation if needed. When the episode is resolved, a prophylactic treatment using inhaled corticosteroids must be prescribed. Clinical and spirometric follow-up has to be organized, and the patient and his/her family have to be educated.

Urinary cotinine and exposure to parental smoking in a population of children with asthma

BACKGROUND

Studies of the effects of tobacco smoke often rely on reported exposure to cigarette smoke, a measure that is subject to bias. We describe here the relationship between parental smoking exposure as assessed by urinary cotinine excretion and lung function in children with asthma.

METHODS

We studied 90 children 4-14 years of age, who reported a confirmed diagnosis or symptoms of asthma. In each child, we assessed baseline pulmonary function (spirometry) and bronchial responsiveness to carbachol stimulation. Urinary cotinine was measured by HPLC with ultraviolet detection.

RESULTS

Urinary cotinine concentrations in the children were significantly correlated (P <0.001) with the number of cigarettes the parents, especially the mothers, smoked. Bronchial responsiveness to carbachol (but not spirometry test results) was correlated (P <0.03) with urinary cotinine in the children.

CONCLUSION

Passive smoke exposure increases the bronchial responsiveness to carbachol in asthmatic children.

Pulmonary anthracosis in children

We report two cases of children with malignancies and subpleural nodules found on computed tomography (CT) scan. In both cases the diagnosis was anthracosis. This pathologic condition has never been reported in children. Causes of anthracosis include a smoking environment, living in urban areas and air pollution.

Bronchial challenge with carbachol in 3-6-year-old children: body plethysmography assessments

Several studies of airway responsiveness in young children (3-6 years old) have been reported, but few have attempted measurements of airway resistance by body plethysmography. Therefore, we decided to study nonspecific bronchial responsiveness following cumulative doses of inhaled carbachol in 44 children with clinical asthma (CA group), 44 children with chronic cough (CC group), 38 children with wheezy bronchitis in the first 2 years of life (WB group), and 40 controls. Specific airway resistance (sRaw) was measured in a body plethysmograph, and specific airway conductance (sGaw=1/sRaw) was calculated. Two parameters were used to assess individual bronchial responses: 1) PD100 (the dose of carbachol which induced a 100% increase in sRaw), and 2) bronchial reactivity (BR), i.e., the slope of the log-dose sGaw response to carbachol. Significant differences were observed in PD100 and BR between the control group and the three groups of young patients (P < 0.001). Moreover, PD100 of the CA group was significantly lower than in the CC group (83.1 +/- 7.8 microg vs. 108.0 +/- 10.2 microg, respectively, P < 0.05), but was similar to the WB group PD100 (94.4 +/- 8.5 microg). BR in the CA group was significantly higher than in both the CC and WB groups (0.127 +/- 0.009 cm H2O-L.sec(-1) x log microg(-1) vs. 0.073 +/- 0.006 cm H2O(-1) x sec(-1) x log microg(-1) and 0.082 +/- 0.006 cm H2O(-1) x sec(-1) x log microg(-1), respectively, P < 0.001). Repeatability and coefficients of variation were always acceptable. Continuous SaO2 monitoring in some children of the CA group demonstrated the safety of the method, which is proposed as a technique in future studies.

Possible interaction between exposure to environmental tobacco smoke and therapy in children with asthma

1. The aim of the study was to determine the carbachol and albuterol responsiveness in treated and untreated asthmatic and allergic children exposed to environmental tobacco smoke assessed by urinary cotinine measurements. 2. Forty-six asthmatic and allergic children with normal spirometric values were recruited. The doubling dose, concentration of carbachol producing a 2-fold increase in specific airway resistance (SRaw) was determined and 200 micrograms of albuterol were administered via a Volumatic(R) spacer. The percentage of bronchodilatation was defined as the difference between the largest obtained SRaw and the post-beta2 SRaw divided by the largest SRaw. Data were compared by a Mann-Whitney U-test. 3. The 23 children with a high urinary cotinine, compared with the 23 children without urinary cotinine, had a decreased doubling dose (108.2+/-14.7 micrograms versus 160.9+/-19.5 micrograms; P=0.04) and an increased percentage of bronchodilatation (74.8+/-1.4% versus 68.8+/-1.8%; P=0.03). A prophylactic anti-inflammatory treatment induced a weaker bronchial reactivity to carbachol and a slightly greater bronchodilatation in children exposed to environmental tobacco smoke. 4. Environmental tobacco smoke increases bronchial reactivity in asthmatic and allergic children. This effect might be reduced by anti-inflammatory therapy. The bronchodilator response may be enhanced in exposed children and may be caused by one or several direct interactions between tobacco smoke compounds and albuterol.

[Influence of the inhaler device on bronchodilatation in the asthmatic child]

The use of spacer devices is recommended in asthmatic children for inhaled therapeutics. Therefore, in vitro studies prove the dependent-device delivery of the drug. The aim of this study was to compare, in vivo, the effect of 200 micrograms of albuterol, delivered via one of the five spacer devices currently marketed in France (Aerochamber, Aeroscopic, Babyhaler with a face mask, Nebuhaler or Volumatic) and assessed by the induced peak expiratory flow (PEF) change. One hundred asthmatic children were recruited and randomized in 5 groups. The mean age was 8.9 +/- 3.3 years. Each group was comparable regardless of gender, height, weight, characteristics of asthma and baseline PEF. The maximal change in PEF was obtained with Babyhaler (14.9 +/- 12.8%; p = 0.009). The increase in PEF elicited with Aeroscopic was 9.7 +/- 10.2%. The others spacer devices did not offer a change greater than the variation of PEF in the studied population. Further studies, concerned with a measurement of drug deposition or with an assessment of its use in obstructive episodes of asthma, are required, but Babyhaler with a face mask, usually reserved to infants, deserves to be advised to older children for salbutamol intake.